A recent double-blinded, peer-reviewed analysis published in Cancer Letters revealed that the experimental test correctly identified 71% of pancreatic cancer samples in the lab compared to only 44 ...
(Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced ...